The last minute, two-year suspension of the device excise tax that went through last month wasn't exactly what Mark Leahey, president and CEO of the Medical Device Manufacturers Association, had in mind at the start of 2017 when all cylinders were firing at MDMA and aligned groups for a permanent repeal. But, "with the political environment we're in right now," companies are satisfied that the tax was temporarily turned off before the first payments were due Jan. 29, he said in an interview.
Podcast: DC Reflections – Mark Leahey On MDMA's 2018 Priorities And The Medtech Landscape
In an interview with Medtech Insight, MDMA CEO Mark Leahey talked about the industry group's ongoing efforts to fully repeal the medical device tax, reimbursement challenges, cybersecurity and more. Check out the summary, the podcast and the transcript.
More from Regulation
• By
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
About 200 staff in the FDA’s Center for Devices and Radiological Health were among the 3,500 FDA employees let go in today’s staff reductions. The cuts, which one employee described as a “Manhattan Project” to the center, are already having a major effect on staff morale.
AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.
More from Policy & Regulation
• By
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.